How we build
biosimilars
Precision at every transition
Our biosimilar capabilities are built to expand access to lifesaving and life-improving therapies for people everywhere.
We use large-molecule expertise to create biosimilars matching the reference product in safety and efficacy, while ensuring affordability through smart development and scalable manufacturing.
One system.
Every stage.
Development & Manufacturing
We combine analytical characterization, process development, and formulation expertise to establish biosimilarity and build efficient, scalable processes.
Cost efficiency is built in from the start, helping programs remain commercially viable long after launch.
Cell line, process development, and formulation
GMP manufacturing built for compliance and scale
Device and delivery development -pre-filled syringe expertise
Tech transfer managed end-to-end
Continuous improvement embedded across the full development lifecycle
Clinical development in a lean and tailored approach
Clinical
We align clinical development planning with CMC and regulatory workstreams, supporting efficient dossier preparation and inspection readiness — so approval isn't a late-stage surprise.
Every efficiency we build into this stage shortens the path between a therapy and the people who need it.
One unified regulatory strategy
Implementing tailored clinical strategies and execution
Dossiers build for global submissions.
Inspection readiness from the start
Regualtory, IP & Quality
Quality isn't a checkpoint -it's everywhere, embedded across the full partner network, not just within our own walls -through clear governance and lifecycle accountability.
From day one, we prioritize documentation and reproducible processes, making inspection readiness a natural outcome of our work.
Documentation and quality discipline from day one
Reproducible, inspection-ready processes
Continuous oversight across the partner network
Lifecycle Management
Approval isn't the finish line. We remain accountable for the commercial sustainability of every program long after launch -first in, last out -managing post-approval changes, label extensions, and long-term supply so biosimilars stay viable and available.
We keep improving cost efficiency throughout, because the work of making a program the best it can be doesn't stop at launch.
Post-approval changes handled in-house
Label extensions and process updates
Continuous cost efficiency improvements, even after launch
Accountable long after launch -first in, last out
The right partner changes everything
Our partnerships are built on trust, ownership, and long-term commitment.
